No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls

Mol Cell Probes. Apr-Jun 2011;25(2-3):134-6. doi: 10.1016/j.mcp.2011.01.005. Epub 2011 Jan 31.

Abstract

New ELISA assays were developed to measure immunoreactivity for XMRV. Antibody titers were measured in a cohort of prostate cancer cases and cancer free controls from the central United States. No statistically significant differences were observed in immunoreactivity between cases and controls for either the XMRV-env or the XMRV-gag antigen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / immunology*
  • Cohort Studies
  • Enzyme-Linked Immunosorbent Assay / methods
  • Gene Products, env / immunology
  • Humans
  • Male
  • Prostatic Neoplasms / immunology*
  • Prostatic Neoplasms / virology
  • Reproducibility of Results
  • Retroviridae Infections / diagnosis
  • Retroviridae Infections / immunology*
  • Retroviridae Infections / virology
  • Sensitivity and Specificity
  • Xenotropic murine leukemia virus-related virus / immunology*

Substances

  • Antibodies, Viral
  • Gene Products, env